Hematologic profiles with bortezomib in relapsed MM

被引：0
|
作者：
Lonial, S.
Richardson, P. G.
Miguel, J. San
Sonneveld, P.
Schuster, M.
Blade, J.
Cavenagh, J.
Rajkumar, V.
Jakubowiak, A.
Esseltine, D.
Anderson, K. C.
Harousseau, J.
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Hosp Univ Salamanca, Salamanca, Spain
[4] Univ Rotterdam Hosp, Rotterdam, Netherlands
[5] NY Presbyterian Hosp, New York, NY USA
[6] Univ Barcelona, Barcelona, Spain
[7] St Bartholomews Hosp, London, England
[8] Mayo Clin, Rochester, MN USA
[9] Univ Michigan, Ann Arbor, MI 48109 USA
[10] Millennium Pharmaceut Inc, Cambridge, MA USA
[11] Hop Hotel Dieu, Nantes, France
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
MULTIPLE-MYELOMA; REFRACTORY MYELOMA; PHASE-2;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：159 / 160
页数：2
相关论文
共 50 条
  • [21] Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study
    Anderson, K. C.
    Jagannath, S.
    Jakubowiak, A.
    Lonial, S.
    Raje, N.
    Alsina, M.
    Ghobrial, I.
    Knight, R.
    Esseltine, D.
    Richardson, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Dose escalating trial of 17-AAG with bortezomib (BZ) in patients with relapsed refractory multiple myeloma (MM).
    Chanan-Khan, A
    Alsina, M
    Carroll, M
    Landrigan, B
    Doss, D
    Albitar, M
    Mitsiades, C
    Cropp, GF
    Hannah, AL
    Richardson, PG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 605S - 605S
  • [23] Bortezomib dosing in relapsed multiple myeloma
    Jagannath, Sundar
    CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (02): : 101 - 102
  • [24] Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts)
    Badros, A. Z.
    Philip, S.
    Niesvizk, R.
    Goloubeva, O.
    Harris, C.
    Zweibel, J.
    Wright, J. J.
    Burger, A.
    Baer, M. R.
    Egorin, M. J.
    Grant, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] PHASE I TRIAL OF VORINOSTAT PLUS BORTEZOMIB (BORT) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS (PTS)
    Badros, Z.
    Philip, S.
    Niesvizky, R.
    Goloubeva, O.
    Harris, C.
    Zweibel, J.
    Wright, J.
    Burger, A.
    Baer, M.
    Egorin, M.
    Grant, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 258 - 258
  • [26] LENALIDOMIDE VERSUS BORTEZOMIB FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM): A NUMBER NEEDED TO TREAT (NNT) ANALYSIS
    Kaura, S.
    Dranitsaris, G.
    VALUE IN HEALTH, 2012, 15 (07) : A654 - A654
  • [27] Phase 1 clinical trial of KOS-953+Bortezomib (BZ) in relapsed refractory multiple myeloma (MM)
    Chanan-Khan, AA
    Richardson, PG
    Alsina, M
    Carroll, M
    Lonial, S
    Krishnan, A
    Albitar, M
    Zhou, Y
    Mitsiades, C
    Cropp, G
    Hannah, AL
    Anderson, KC
    BLOOD, 2005, 106 (11) : 109A - 110A
  • [28] Bortezomib in Relapsed/Refractory Multiple Myeloma
    Shen, Z.
    Wang, L.
    Yan, H.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S62 - S62
  • [29] Activity of bortezomib in relapsed or refractory lymphoma
    不详
    CLINICAL LYMPHOMA, 2004, 5 (02): : 75 - 76
  • [30] Bortezomib in relapsed or refractory myeloma patients
    Leonetti Crescenzi, S.
    Piccioni, A. L.
    Bagnato, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 208 - 208
12345